Skip to main content Skip to section navigation Skip to footer
Contact

Excision BioTherapeutics, Inc.

  • Home
  • About
    • Overview
    • Leadership Team
    • Board of Directors
    • Business Advisory Board
    • Scientific Advisory Board
    • Excision Team
  • Technology
    • Overview
    • Publications
    • Pipeline
  • Clinical Trials
  • News
    • Press Releases
  • Contact

Press Releases

News

News

  • Press Releases
Nov 21, 2019 12:00pm EST

Excision BioTherapeutics Presents Data to Support HIV Cure Using CRISPR Gene Editing Technology

Nov 18, 2019 12:00pm EST

CRISPR Gene Editing Eliminates Herpes Simplex Virus and JC Virus, Demonstrating Feasibility of a Potential Functional Cure

Jul 02, 2019 11:16am EDT

HIV Eliminated from the Genomes of Living Animals; Excision BioTherapeutics Advancing the Innovation to Clinical Development

Nov 13, 2017 10:01am EST

Excision BioTherapeutics Exclusively Licenses New CRISPR-Cas Gene Editors from UC Berkeley, to be Used for Viral Infections

Sep 06, 2017 10:00am EDT

HIV Cure-Focused Excision BioTherapeutics Secures $10 Million in Seed Funding Led by ARTIS Ventures

Mar 21, 2016 5:31pm EDT

Use of CRISPR Cas9 Gene Editing Therapeutic Shown to Permanently Inactivate HIV-1 in Patient's Blood for First Time

  • arrow_back
  • 1
  • 2
  • 3
  • 4
  • 5
rss_feed News RSS

Join Excision

Our team of dedicated experts is on a mission to improve the lives of patients with viral diseases. Come join us.

  • Visit us on Facebook
  • Visit us on Twitter
  • Visit us on Linkedin
  • Visit us on Instagram
Privacy Policy Disclaimer Sitemap Terms of Use
©2025 Excision BioTherapeutics, Inc. All Rights Reserved.

Headquarters

134 Coolidge Avenue • Watertown, MA • 02472 • USA